SEC EDGAR · company profile · free

GILEAD SCIENCES, INC. due diligence

Who GILEAD SCIENCES, INC. (GILD) is on the public record: identity, annual results, what it filed in the last year and why, straight from SEC EDGAR.

1000 filings in EDGAR's recent index, 560 of them Form 4 insider filings · view the filings on SEC EDGAR · source: SEC EDGAR submissions index and XBRL financial data

At a glance

GILEAD SCIENCES, INC. (GILD) is a large accelerated filer incorporated in Delaware, classified under SIC 2836 (Biological Products, (No Diagnostic Substances)), and lists on Nasdaq. Its fiscal year ends December 31. It has also filed as GILEAD SCIENCES INC.

For the fiscal year ended December 31, 2025, its 10-K reported revenue of $29.4B, up 2.4% from the year before, net income of $8.5B, and total assets of $59.0B.

In the twelve months to October 9, 2026 it made 171 filings on EDGAR, including 1 annual report, 3 quarterly reports, 9 current reports on Form 8-K, and 85 Form 4 insider filings, plus 3 prospectus supplements and free writing prospectuses for its securities offerings. Its 8-Ks were filed most often for results of operations (4), a material agreement (2), and Regulation FD disclosures (2).

CIK
0000882095
Filer status
Large accelerated filer
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
Incorporated
Delaware
Listed on
Nasdaq
Tickers
GILD
Fiscal year end
12-31

Annual results

Fiscal year endedRevenueNet incomeTotal assets
2025-12-31$29.4B +2.4%$8.5B +1672.9%$59.0B
2024-12-31$28.8B +6.0%$480M -91.5%$59.0B
2023-12-31$27.1B$5.7B$62.1B
As reported in each 10-K's XBRL data on SEC EDGAR (revenue tag RevenueFromContractWithCustomerExcludingAssessedTax); a later 10-K's restatement replaces the earlier figure.
FilingFiledPeriodAccession
Annual report (10-K)2026-02-242025-12-310000882095-26-000006
Quarterly report (10-Q)2026-08-062026-06-300000882095-26-000031
Current report (8-K)2026-08-042026-08-040000882095-26-000028

Filing activity

171 filings since 2025-10-09, 3 of them prospectus supplements and free writing prospectuses (not listed below). By form:

4
85
144
43
8-K
9
13F-HR
4
SCHEDULE 13D/A
4
10-Q
3
SC TO-T/A
3
SCHEDULE 13G/A
3

8-K items in the last 12 months: results of operations (Item 2.02, 4) · a material agreement (Item 1.01, 2) · Regulation FD disclosures (Item 7.01, 2) · other events (Item 8.01, 2) · a new financial obligation (Item 2.03, 1) · officer or director changes (Item 5.02, 1) · shareholder vote results (Item 5.07, 1).

FiledFormDocumentPeriod
2026-10-024FORM 42026-10-01
2026-09-234FORM 42026-09-22
2026-09-164FORM 42026-09-15
2026-09-164FORM 42026-09-15
2026-09-15144Form 144 notice of proposed sale
2026-09-15144Form 144 notice of proposed sale
2026-09-114FORM 42026-09-10
2026-09-114FORM 42026-09-10
2026-09-114FORM 42026-09-10
2026-09-114FORM 42026-09-10
free alert

Free. One email a day at most, only when something changes. Confirm by email first; unsubscribe with one click. Privacy.

The full due-diligence dossier on GILEAD SCIENCES, INC.

The free view above is identity and filing dates. The paid dossier reads the filings: business and segments, financial trend, insider and institutional activity, litigation and risk-factor themes, recent news, and the red flags, every claim cited and delivered with a data appendix.

agents: POST /v1/dossier with {"ticker":"GILD"} over x402 or MPP, $0.85

Sample output and API docs · all reports

GILD insider filingsAll company profiles13F fund holdingsAll reports

Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.